Despite recent advances in non-invasive markers of neurodegeneration (eg, tau variants for Alzheimer’s disease, neurofilament light protein for multiple sclerosis), there are no validated laboratory biomarkers for the assessment of disease progression in Wolfram syndrome. This evidence concerns the gene MAPT and Alzheimer disease.